# US 8,278,334 B2 · Cyclic amine BACE-1 inhibitors having a benzamide substituent

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 8,278,334 B2
- Document ID: US8278334B2
- Status: Granted
- Kind: B2
- Application number: 12/641,952
- Filed: 2009-12-18
- Published: 2010-06-17
- Granted: 2012-10-02
- Earliest claimed: 2003-08-08
- Assignees: Merck Sharp & Dohme Corp.
- Inventors: Jared N. Cumming; Ulrich Iserloh; Andrew Stamford; Corey Strickland; Johannes H. Voigt; Yusheng Wu; Ying Huang; Yan Xia; Samuel Chackalamannil; Tao Guo; Douglas W. Hobbs; Thuy X. H. Le; Jeffrey F. Lowrie; Kurt W. Saionz; Suresh D. Babu
- Web page: https://patentgrep.com/patent/US8278334B2

## CPC

- C07D 243/08: not condensed with other rings
- A61P 25/00: Drugs for disorders of the nervous system
- A61P 25/28: for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C07D 205/04: having no double bonds between ring members or between ring members and non-ring members
- C07D 207/08: with hydrocarbon radicals, substituted by hetero atoms, attached to ring carbon atoms
- C07D 207/09: Radicals substituted by nitrogen atoms, not forming part of a nitro radical
- C07D 207/12: Oxygen or sulfur atoms
- C07D 207/26: 2-Pyrrolidones
- C07D 209/52: condensed with a ring other than six-membered
- C07D 211/26: with hydrocarbon radicals, substituted by nitrogen atoms
- C07D 211/46: having a hydrogen atom as the second substituent in position 4
- C07D 217/18: Aralkyl radicals
- C07D 233/32: One oxygen atom
- C07D 241/04: having no double bonds between ring members or between ring members and non-ring members
- C07D 241/08: with oxygen atoms directly attached to ring carbon atoms
- C07D 401/06: linked by a carbon chain containing only aliphatic carbon atoms
- C07D 401/10: linked by a carbon chain containing aromatic rings
- C07D 401/12: linked by a chain containing hetero atoms as chain links
- C07D 403/12: linked by a chain containing hetero atoms as chain links
- C07D 403/14: containing three or more hetero rings
- C07D 409/06: linked by a carbon chain containing only aliphatic carbon atoms
- C07D 409/12: linked by a chain containing hetero atoms as chain links
- C07D 413/06: linked by a carbon chain containing only aliphatic carbon atoms
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Disclosed are compounds of the formula or a pharmaceutically acceptable salt or solvate thereof, wherein R1 is R is —C(O)—N(R27)(R28) or and the remaining variables are as defined in the specification. Also disclosed are pharmaceutical compositions comprising the compounds of formula I. Also disclosed are methods of treating cognitive or neurodegenerative diseases such as Alzheimer's disease. Also disclosed are pharmaceutical compositions and methods of treating cognitive or neurodegenerative diseases comprising the compounds of formula I in combination with a β-secretase inhibitor other than those of formula I, an HMG-CoA reductase inhibitor, a gamma-secretase inhibitor, a non-steroidal anti-inflammatory agent, an N-methyl-D-aspartate receptor antagonist, a cholinesterase inhibitor or an anti-amyloid antibody.

## Claims

### Claim 1

A compound having the structural formula
or a pharmaceutically acceptable salt thereof, wherein
R1 is
R is —C(O)—N(R27)(R28);
R2 is difluorobenzyl;
R3 is H or alkyl;
R4 is H or alkyl;
R8 is selected from the group consisting of H, OH, alkoxy, phenoxy or benzyloxy, wherein said alkoxy, said phenoxy, and said benzyloxy are unsubstituted or substituted by 1 to 5 independently selected R32 groups;
R14 is 1 to 4 substituents independently selected from the group consisting of H, alkyl, halo, —CN, haloalkyl,
R27 and R28 are independently selected from alkyl, cycloalkyl, cycloalkylalkyl, aryl, arylalkyl, hydroxyalkyl, and alkoxyalkyl;
or R27 and R28 together with the nitrogen to which they are attached, form an unsubstituted 3-7 membered heterocycloalkyl ring, or a 3-7 membered heterocycloalkyl ring substituted by 1-3 substituents independently selected from the group consisting of alkyl, and alkoxyalkyl;
wherein each R32 group is independently selected from the group consisting of halo, alkyl, cycloalkyl, cycloalkylalkyl, and —OR35;
each R35 is independently selected from the group consisting of H and alkyl.

### Claim 2 (depends on 1)

A compound of claim 1 wherein R3 and R4 are hydrogen.

### Claim 3 (depends on 1)

A compound of claim 1 wherein R1 is

### Claim 4 (depends on 1)

A compound of claim 1 having the stereochemical structure:

### Claim 5 (depends on 1)

A compound of claim 1 selected from the group consisting of

### Claim 6 (depends on 1)

The compound of claim 1 which is

### Claim 7 (depends on 1)

A pharmaceutical composition comprising an effective amount of a compound of claim 1 and a pharmaceutically effective carrier.

### Claim 8 (depends on 1)

A pharmaceutical composition comprising an effective amount of a compound of claim 1, and an effective amount of a β-secretase inhibitor other than those of formula I, an HMG-CoA reductase inhibitor, a gamma-secretase inhibitor, a non-steroidal anti-inflammatory agent, an N-methyl-D-aspartate receptor antagonist, a cholinesterase inhibitor or an anti-amyloid antibody in a pharmaceutically effective carrier.

### Claim 9 (depends on 8)

A composition of claim 8 wherein the HMG-CoA reductase inhibitor is selected from the group consisting of atorvastatin, lovastatin, simvistatin, pravastatin, fluvastatin and rosuvastatin; the cholinesterase inhibitor is selected from the group consisting of atorvastatin, lovastatin, simvistatin, pravastatin, fluvastatin and rosuvastatin; the non-steroidal anti-inflammatory agent is selected from the group consisting of ibuprofen, naproxen, diclofenac, diflunisal, etodolac, flurbiprofen, indomethacin, ketoprofen, ketorolac, nabumetone, oxaprozin, piroxicam, sulindac, tolmetin, celecoxib and rofecoxib; and the N-methyl-D-aspartate receptor antagonist is memantine.

### Claim 10

A kit comprising in separate containers in a single package pharmaceutical compositions for use in combination, in which one container comprises a compound of formula I in a pharmaceutically acceptable carrier and a second container comprises a β-secretase inhibitor other than those of formula I, an HMG-CoA reductase inhibitor, a gamma-secretase inhibitor, a non-steroidal anti-inflammatory agent, an N-methyl-D-aspartate receptor antagonist, a cholinesterase inhibitor or an anti-amyloid antibody in a pharmaceutically acceptable carrier.
